Search

Displaying results 4571 - 4580 of 9895 in total
  1. Drug

    Rimacalib

    go.drugbank.com/drugs/DB12571
    Investigational

    Rimacalib has been used in trials studying the treatment of Rheumatoid Arthritis (RA).

  2. Drug

    OP-145

    go.drugbank.com/drugs/DB05672
    Experimental

    OP-145 is a synthetic antimicrobial peptide developed from human cathelicidin LL-37.

    Synonyms: -GLUTAMYL-L-ARGINYL-L-ISOLEUCYL-L-LYSYL-L-ARGINYL-L-PHENYLALANYL-L-LEUCYL-L-ARGINYL-L-.ALPHA.-GLUTAMYL-L-LEUCYL-L-VALYL-L-ARGINYL-L-PRO, L-ARGININE, L-ISOLEUCYLGLYCYL-L-LYSYL-L-.ALPHA.-GLUTAMYL-L-PHENYLALANYL-L-LYSYL-L-ARGINYL-L-ISOLEUCYL-L-VALYL-L-.ALPHA.
  3. Drug

    Medical Cannabis

    go.drugbank.com/drugs/DB14009
    Investigational

    Due to the differences in receptor profile between CBD and THC, these cannabinoids are understandably used to treat different conditions. … This area of research is controversial and has been heavily debated, however, due to concerns over risks of addiction, long-term health effects, and Cannabis' association with schizophrenia.

  4. Drug

    Ixazomib

    go.drugbank.com/drugs/DB09570
    ApprovedInvestigational

    Ixazomib is a reversible proteasome inhibitor. Because it is a modified peptide boronic acid with one chiral center,[A264329] it is considered a boronate proteasome inhibitor. … [L51244] It was also investigated in other hematological malignancies as well as other conditions, such as systemic light chain (AL) amyloidosis, graft-versus-host disease, and lupus nephritis.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  5. Drug

    Nerinetide

    go.drugbank.com/drugs/DB12595
    Investigational

    Na 1 is under investigation in clinical trial NCT00728182 (Evaluating Neuroprotection in Aneurysm Coiling Therapy).

    Synonyms: L-TYROSYLGLYCYL-L-ARGINYL-L-LYSYL-L-LYSYL-L-ARGINYL-L-ARGINYL-L-GLUTAMINYL-L-ARGINYL-L-ARGINYL-L-ARGINYL-L-LYSYL-L-LEUCYL-L-SERYL-L-SERYL-L-ISOLEUCYL-L-.ALPHA.-GLUTAMYL-L-SERYL-L-.ALPHA., L-VALINE, L-TYROSYLGLYCYL-L-ARGINYL-L-LYSYL-L-LYSYL-L-ARGINYL-L-ARGINYL-L-GLUTAMINYL-L-ARGINYL-L-ARGINYL-L-ARGINYL-L-LYSYL-L-LEUCYL-L-SERYL-L-SERYL-L-ISOLEUCYL-L-.ALPHA.-GLUTAMYL-L-SERYL-L-.ALPHA.
  6. Drug

    Zuretinol acetate

    go.drugbank.com/drugs/DB12112
    Investigational

    Zuretinol acetate has been used in trials studying the treatment of Impaired Dark Adaptation, RP (Retinitis Pigmentosa), Retinitis Pigmentosa (RP), and LCA (Leber Congenital Amaurosis).

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    LY-2624803

    go.drugbank.com/drugs/DB15092
    Investigational

    LY-2624803 is under investigation in clinical trial NCT01236105 (Effect of Activated Charcoal and Time of Dose on the Pharmacokinetics of LY2624803 in Healthy Subject).

  8. Drug

    Ramoplanin

    go.drugbank.com/drugs/DB04952
    Experimental

    Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD.

  9. Drug

    Erfonrilimab

    go.drugbank.com/drugs/DB17446
    Investigational

    Erfonrilimab is a bispecific monoclonal antibody directed against both the programmed cell death-1 ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4).

  10. Drug

    Trilaciclib

    go.drugbank.com/drugs/DB15442
    ApprovedInvestigational

    Trilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing